title: [Treatment of ovarian cancer cell line Skov3 with HSV-tk/GCV under the control of human telomerase reverse transcriptase gene promoter].
abstract: OBJECTIVE
  To investigate the in vitro effect of HSV-tk/GCV using a hTERT promoter-driven vector system on Skov3 ovarian cancer cells.
  
  
  METHODS
  An expression vector (pBTdel-279-tk) containing tk gene under the hTERT promoter was constructed by molecular biological methods, and then was transfected into Skov3 ovarian cancer cells, normal ovarian epithelial cells (NOEC) and human embryonic lung fibroblast by cationic liposome. Following the transfection with tk, GCV was added, and MTT and flow cytometry methods were applied to investigate its antitumor effect. RT-PCR was used to detect the tk gene in ovarian cancer cells and normal cells after the transfection of pcDNA3-tk or pBTdel-279-tk.
  
  
  RESULTS
  pBTdel-279-tk/GCV system induced apoptosis in hTERT-positive ovarian cancer cells, but not in hTERT-negative normal ovarian epithelial cells and fibroblasts. The hTERT promoter system was almost as efficient in inducing cancer cell death as the CMV promoter. tk gene was expressed in Skov3 cells and NOEC after pcDNA3-tk transfection, while positive was only in ovarian cancer cells after pBTdel-279-tk transfection.
  
  
  CONCLUSIONS
  The telomerasespecific transfer of the tk gene under the hTERT promoter is a novel targeting approach for the treatment of ovarian cancer and may lead to an effective and specific gene therapy.
authors.affiliation: Department of Obstetrics and Gynocology, Qilu Hospital of Shandong University, Jinan 250012, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Song
authors.forename: Bei-hua
authors.initials: BH
authors.lastname: Kong
authors.forename: Pei-shu
authors.initials: PS
authors.lastname: Liu
authors.forename: Dao-xin
authors.initials: DX
authors.lastname: Ma
authors.forename: Xun
authors.initials: X
authors.lastname: Qu
authors.forename: Sen
authors.initials: S
authors.lastname: Jiang
mesh_terms: D017209:Apoptosis / Q000235:genetics*; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000473:pathology; D004268:DNA-Binding Proteins; D005260:Female; D015774:Ganciclovir / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D011401:Promoter Regions, Genetic / Q000235:genetics*; D018139:Simplexvirus / Q000235:genetics; D019098:Telomerase / Q000235:genetics*; D013937:Thymidine Kinase / Q000235:genetics*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D013937:Thymidine Kinase; D019098:Telomerase; D015774:Ganciclovir